The North American Age-related Macular Degeneration (AMD) drugs market is dedicated to creating and supplying advanced prescription medicines that help treat AMD, a major cause of vision loss in older people. This industry primarily focuses on therapies, such as anti-VEGF agents often administered through eye injections, to manage the severe, rapid vision loss caused by Wet AMD, but it is also expanding rapidly to introduce the first treatments for the more common Dry AMD. The market is constantly innovating with new drugs and drug delivery systems that can extend the time between treatments, aiming to provide more convenient and effective care for the region’s increasing number of patients with this chronic eye condition.
Download PDF BrochureInquire Before Buying
The North American Age-related Macular Degeneration drugs Market was valued at $XX billion in 2025, will reach $XX billion in 2026, and is projected to hit $XX billion by 2030, growing at a robust compound annual growth rate (CAGR) of XX%.
The global age-related macular degeneration (AMD) drugs market was valued at 9.55 billion dollars in 2023, reached 10.46 billion dollars in 2024, and is projected to grow at a robust 10.7% Compound Annual Growth Rate (CAGR), reaching 17.37 billion dollars by 2029.
Drivers
The primary driver for the North American AMD drugs market is the rapidly increasing geriatric population, which is highly prone to retinal diseases. AMD is a leading cause of vision impairment in older adults. The US alone reports approximately 200,000 new cases of wet AMD annually, creating a massive, continuous patient pool and strong demand for effective therapeutic agents and advanced diagnostics for both wet and dry forms of the disease, directly boosting market revenue.
North America, particularly the US, benefits from a robust and advanced healthcare infrastructure with high R&D capabilities. This mature system, coupled with significant governmental and private funding, supports the development and clinical trials of novel AMD drugs. The presence of major pharmaceutical research-oriented institutions accelerates the product pipeline, encouraging continuous innovation in drug formulations and delivery systems, which is crucial for market growth.
The continuous approval of new and highly effective AMD drugs, including biosimilars like Enzeevu for wet AMD and novel therapies like Syfovre for dry AMD, fuels market expansion. High market penetration of established anti-VEGF agents like Eylea and Lucentis, driven by strong preference from ophthalmologists and favorable reimbursement policies, ensures high adoption rates across the diverse patient pool in the region.
Restraints
A major restraint is the need for frequent intravitreal injections, which is the dominant route of administration (92%). This invasive procedure poses a significant burden on patients, requiring regular hospital visits and carrying risks like endophthalmitis. The regimen’s invasiveness often leads to patient non-compliance, which can negatively affect long-term treatment outcomes and limit the overall therapeutic efficacy across the patient population.
The high cost of patented, branded anti-VEGF agents, such as Eylea and Vabysmo, acts as a substantial restraint. Although government programs and private insurers provide coverage, out-of-pocket costs and complex reimbursement procedures can still pose financial barriers, especially for patients with limited or inconsistent insurance coverage, which limits broad and timely access to optimal care.
Stringent and time-consuming regulatory approval processes, particularly with the US FDA, create a significant bottleneck for bringing novel AMD drugs to market. Clinical trials for retinal diseases require long follow-up periods and complex endpoints. Furthermore, existing regulatory compliance issues faced by key players can create market uncertainty and slow down the pace of commercialization for new, cutting-edge therapies.
Opportunities
The dry AMD segment presents a huge untapped opportunity, as it accounts for nearly 90% of all AMD cases. Recent FDA approvals for complement inhibitors like Syfovre and Izervay, the first treatments for advanced dry AMD, have validated this segment. This success is now spurring immense investment in the development of a robust pipeline of new therapies, ensuring significant market expansion beyond the established wet AMD treatment paradigm.
A key opportunity lies in the development and commercialization of Gene and Cell Therapies for both wet and dry AMD. These emerging treatments offer the potential for single-injection, long-term therapeutic effects, which would radically improve patient compliance and quality of life. High R&D funding in North America is accelerating the progression of these groundbreaking therapies from clinical trials to market.
Opportunities exist in developing new drug formulations and delivery systems that extend the dosing intervals and enhance patient compliance. This includes new sustained-release drug implants and alternative delivery mechanisms that aim to reduce the frequency of intravitreal injections. Such innovations directly address a key patient pain point and are expected to significantly boost market adoption and patient adherence.
Challenges
A significant challenge is the intense competition and market saturation within the wet AMD drug space, which is dominated by leading anti-VEGF agents. The entry of biosimilars, such as Enzeevu, for existing blockbuster drugs will increase price competition. Companies must continuously innovate to differentiate their products based on superior efficacy, extended dosing regimens, or reduced side effects to maintain market share.
The market is still challenged by the profound unmet medical need for effective and approved treatments for the early and intermediate stages of dry AMD. While late-stage dry AMD has new therapies, a lack of preventative or early-stage disease-modifying drugs remains a major hurdle. This gap limits the ability to intervene early and slow the progression of vision loss for the vast majority of AMD patients.
Another key challenge lies in sustaining the high cost of innovation, particularly for novel gene and cell therapies, while navigating complex reimbursement landscapes. Demonstrating the long-term cost-effectiveness and securing favorable coverage for these premium-priced, one-time or infrequent treatments is crucial. Failing to do so will severely restrict patient access and slow the market’s adoption of the next generation of AMD drugs.
Role of AI
Artificial Intelligence is becoming indispensable in the early stages of AMD drug discovery. AI algorithms analyze vast genomic, proteomic, and clinical datasets to identify novel drug targets, particularly for complex, multifactorial dry AMD. This accelerates the screening of compounds, predicts molecular activity, and significantly reduces the time and cost associated with the traditional, labor-intensive preclinical research phases.
AI and machine learning models are being leveraged to optimize clinical trial efficiency for AMD drugs. They can predict patient response to therapies, identify ideal trial candidates based on risk factors and disease progression, and analyze complex retinal imaging data. This targeted approach streamlines recruitment, reduces trial duration, and improves the statistical power of studies, accelerating new drug approvals.
In the clinical setting, AI-powered image analysis of Optical Coherence Tomography (OCT) scans enhances diagnostic precision for AMD. AI can detect subtle signs of disease progression, quantify fluid accumulation, and monitor treatment response more accurately than the human eye. This capability is vital for personalized dosing and monitoring, enabling timely intervention and maximizing the therapeutic efficacy of AMD drugs.
Latest Trends
The most significant trend is the paradigm shift towards effective treatments for dry AMD, exemplified by the launch of pegcetacoplan (Syfovre). This represents a major market expansion, moving beyond the current focus on wet AMD. The trend signals a continuous pipeline of complement-inhibitor and neuroprotective drugs, driving considerable investment to address the disease’s vast unmet need.
A strong trend is the introduction of high-dose and extended-interval anti-VEGF formulations, such as Eylea HD, to reduce the frequency of patient injections. This innovation directly addresses patient burden and improves treatment adherence. Drug developers are focused on creating longer-acting molecules and sustained-release delivery technologies to maintain visual gains with fewer clinical visits.
The introduction and growing adoption of anti-VEGF biosimilars, such as Enzeevu, are a crucial trend reshaping the cost structure of the wet AMD market. Biosimilars offer clinically equivalent efficacy at a lower price point, driving competitive pricing. This trend is expected to increase patient access and affordability, leading to cost savings for the healthcare system while maintaining high-quality patient care.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37446234